Altimmune - ALT STOCK NEWS

Altimmune has announced the enrollment of the first patient in a 12-week Phase 1b clinical trial for pemvidutide aimed at treating non-alcoholic fatty liver disease (NAFLD). Led by Dr. Stephen Harrison, the trial aims to include approximately 72 patients and is expected to read out topline data in the first half of 2022. Pemvidutide, a dual receptor agonist, has shown promising results in weight loss and metabolic health, with plans to initiate a Phase 2 NASH study based on the findings from this trial.

Altimmune, Inc. (Nasdaq: ALT) announced a Key Opinion Leader (KOL) call discussing its 12-week Phase 1 clinical trial of pemvidutide on September 30, 2021. The call will feature Dr. Stephen A. Harrison, an expert in non-alcoholic steatohepatitis (NASH), who will review safety and weight loss data. In the trial, subjects taking pemvidutide achieved significant weight losses of 4.9%, 10.3%, and 9.0% across different doses, whereas the placebo group lost only 1.6%. No serious adverse events were reported. Altimmune positions this treatment as crucial for addressing obesity and NASH.

Altimmune has reported promising results from a Phase 1 trial of its investigational drug, pemvidutide, intended for obesity and NASH treatment. Subjects receiving the 1.8 mg dose achieved a mean weight loss of 10.3% over 12 weeks, with no treatment discontinuations due to adverse events. The drug was well-tolerated, and the IND for NASH has cleared FDA review. Future clinical studies, including a 12-week NAFLD trial, are set to commence soon. Altimmune plans to initiate a 48-week Phase 2 obesity trial in H1 2022.

Altimmune, Inc. (Nasdaq: ALT) announced the upcoming results of its 12-week Phase 1 clinical trial for ALT-801, aimed at treating obesity, to be released on September 28, 2021. The company will provide details during a conference call and webcast at 8:30 AM ET, which will also be available for replay on its website. This trial represents a significant step in Altimmune's development pipeline focused on obesity and liver diseases, part of its broader strategy to advance next-generation therapeutics.

Altimmune, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be led by CEO Vipin Garg and CMO Scott Harris, with a pre-recorded session available on September 13 at 7 a.m. EST. Altimmune focuses on developing treatments for obesity and liver diseases, including therapies like ALT-801 for NASH and HepTcell™ for chronic hepatitis B. For further details, visit Altimmune's website.

Altimmune, Inc. (Nasdaq: ALT) has announced its financial results for Q2 2021, reporting a cash position of approximately $218 million, enabling ongoing development of its obesity and liver disease pipeline. The interim results from the ALT-801 Phase 1 trial showed a placebo-adjusted weight loss of 6.3% over six weeks. The 12-week data readout for ALT-801 is expected in September 2021, alongside plans for IND applications in NASH and obesity. Revenue was $0.1 million, down from $0.7 million YoY, with a net loss of $24.8 million for the quarter.

Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2021 financial results on August 11, 2021. Management will host a conference call at 8:30 am E.T. to discuss the results and provide further business updates. The conference can be accessed via dial-in or webcast. Altimmune is focused on developing treatments for obesity and liver diseases, with a pipeline that includes therapies for NASH and chronic hepatitis B.

Altimmune (Nasdaq: ALT) has announced the discontinuation of its AdCOVID vaccine development after a Phase 1 trial revealed it was well tolerated but failed to generate adequate immune responses compared to existing COVID-19 vaccines. The focus will shift to advancing its obesity and liver disease programs, notably ALT-801 and HepTcell. Encouraging interim data from the ALT-801 trial indicate significant weight loss in overweight participants. Meanwhile, enrollment challenges in the T-COVID Phase 1/2 trial have led to the decision to halt further enrollment while evaluating future development options.

Altimmune announced interim results from its Phase 1 trial of ALT-801, a dual GLP-1/glucagon receptor agonist, showing a significant 5.4% weight loss at 6 weeks with a 1.8 mg dose, exceeding the 2% target. The treatment was well-tolerated with low nausea rates. Further developments include plans to file an additional IND for an obesity program in 2021 and an anticipated 12-week data readout in Q3 2021. The trial aims to explore ALT-801's effects on liver fat and metabolic conditions, enhancing its therapeutic potential in tackling obesity and NASH.